10.13.23
In a study presented at the 9th joint meeting of the European and American Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS), researchers provided an interim analysis of data from the ENLIGHTEN (NCT04140305) clinical trial. This ad hoc interim analysis documented the safety and efficacy of Zeposia (ozanimod; Bristol Myers Squibb, New York, NY) over 1 year in participants with early relapsing multiple sclerosis (RMS) and revealed improvement in cognitive processing speed in nearly 50% of participants.
ENLIGHTEN is a multicenter, single-arm, open label phase 3b clinical trial designed to document any changes in cognitive processing speed over 3 years as measured by the Symbol Digit Modalities Test (SDMT) in adult participants with RMS who receive treatment with Zeposia. Participants enrolled in the trial met the following criteria:
Results of the ad hoc interim analysis of cognitive processing speed revealed that after 1 year of treatment with Zeposia:
In terms of other outcomes:
Zeposia is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Researchers for this interim study represented a broad range of institutions, including Washington University School of Medicine; The State University of New York, Buffalo; London Health Sciences Center University Hospital; the Neurology Center of San Antonio; The Medical College of Wisconsin; Alabama Neurology Associates; Hope Neurology MS Center; Bristol Myers Squibb; the Kessler Foundation, and Rutgers-New Jersey Medical School.
Candie Jammal, MD; Iago Pinal-Fernandez, MD, PhD; and Andrew L. Mammen, MD, PhD
Denisse Morales-Rodriguez, BS, and Riley Bove, MD, MMSc
